Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy

Seminars in Dialysis

Volumn 18, Issue 4, 2005, Pages 290-295

  Hernandez, Joel D ^a   Wesseling, Katherine ^a   Salusky, Isidro B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; VITAMIN D;

ARTICLE; HUMAN; METABOLISM; RENAL OSTEODYSTROPHY; VITAMIN D DEFICIENCY;

HUMANS; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 23844488455     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18404.x     Document Type: Article

References (57)

1. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502, 1997
2. Naveh-Many T, Silver J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia and vitamin D in the rat. J Clin Invest 86:1313-1319, 1990
3. Coburn JW, Maung HM: Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney Int 63:S49-S53, 2003
4. Goodman WG, Coburn JW, Slatopolsky E, Salusky IB: Renal osteodystrophy in adults and children. In: Favus MJ (ed.). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th ed. Philadelphia: Lippincott-Raven, 1999:347-363
5. Malluche HH, Monier-Faugere MC: The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 4:1631-1642, 1994
6. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982, 1988
7. Mathias RS, Salusky IB, Harmon WH, Paredes A, Emans J, Segre GV, Goodman WG: Renal bone disease in pediatric patients and young adults treated by hemodialysis in a children's hospital. J Am Soc Nephrol 12:1938-1946, 1993
8. Salusky IB, Ramirez JA, Oppenheim WL, Gales B, Segre GV, Goodman WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258, 1994
9. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung C, Kim LY, Keutmann T, Wang CA, Potts JT Jr, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367, 1987
10. Sherrard DJ, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43:436-442, 1993
11. Cohen-Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere Ph, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73:516-524, 1991
12. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150, 1992
13. Hamdy NA, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310:358-363, 1995
14. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, De Bonis E, Darias E, Gonzales-Posada JM, et al.: Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47:1434-1442, 1995
15. Eknoyan G, Levin A, Levin NW: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease - foreword. Am J Kidney Dis 42:S7-S201, 2003
16. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 81:3923-3929, 1996
17. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809, 1998
18. Brossard JH, Yamamoto LN, D'Amour P: Parathyroid hormone metabolites in renal failure: bioactivity and clinical implications. Semin Dial 15:196-201, 2002
19. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290, 1999
20. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468, 2001
21. Gao P, Scheibel S, D'Amour P, John MR, Rao DS, Schmidt-Gayk H, Cantor TL: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614, 2001
22. Salomon R, Charbit M, Gagnadoux MF, Niaudet P, Gao P, Cantor T, Souberbielle JC: High serum levels of a non-(1-84) parathyroid hormone (PTH) fragment in pediatric haemodialysis patients. Pediatr Nephrol 16:1011-1014, 2001
23. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor TL, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761, 2000
24. Divieti P, John MR, Jüppner H, Bringhurst FR: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171-176, 2002
25. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392, 2001
26. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D'Amour P: Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147:123-131, 2002
27. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801-1808, 2003
28. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D: PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348-354, 2002
29. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293, 1999
30. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121, 2000
31. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB: Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205-211, 1998
32. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951, 2004
33. Salusky IB, Goodman WG: Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978-1985, 2001
34. Goodman WG, Salusky IB: Evolution of secondary hyperparathyroidism during daily oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol 90:189-195, 1991
35. Salusky IB, Kuizon BD, Belin T, Ramirez JA, Gales B, Segre GV, Goodman WG: Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907-914, 1998
36. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994
37. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836-844, 1995
38. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
39. 3: humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382, 1986
40. Gonzalez EA, Martin KJ: Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 50:63-70, 1996
41. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26:622-631, 1995
42. Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38:S54-S61, 1990
43. Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N: Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure. Contrib Nephrol 18:92, 1980
44. Favus MJ: Intestinal absorption of calcium, magnesium and phosphorus. In: Coe FL, Favus MJ (eds). Disorders of Bone and Mineral Metabolism. Philadelphia: Lippincott Williams & Wilkins, 2002:48-73
45. Akizawa T, Kurokawa K, Suzuki M: Suppression of PTH by 22-oxacalcitriol (OCT). A placebo controlled study in hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT) [abstract]. J Am Soc Nephrol 8:570A, 1997
46. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490, 2003
47. 2 Study Group. Nephrol Dial Transplant 13(suppl 3):68-72, 1998
48. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
49. Block GA, Martin KJ, De Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
50. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242, 1978
51. Schmitt CP, Ardissino G, Testa S, Appiani AC, Mehls O: Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 18:440-444, 2003
52. Waller S, Ledermann S, Trompeter R, van't Hoff W, Ridout D, Rees L: Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 18:1236-1241, 2003
53. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
54. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
55. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105, 2002
56. Salusky IB, Goodman WG: Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int 48:657-665, 1995
57. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53:1358-1364, 1998